New Product Launch from Pillar Healthcare

Pillar Healthcare Product Range

In 2014, Pillar Healthcare Limited launched pre-Conceive, a fertility supplement developed over a three year period, that was designed to improve both male and female fertility. After the conclusion of a world’s first clinical examination, pre-Conceive was shown to improve all the key fertility and nutritional parameters associated with infertility in both men and women. Since the presentation of these findings, pre-Conceive and Pillar Healthcare have now helped couples in dozens of countries, across every major continent, to conceive and have a happy and healthy pregnancy.

Developing on the success of pre-Conceive, now a multi-award winning fertility supplement recommended and supported by fertility specialists, Pillar Healthcare have developed four new nutritional formulations. These four new innovative formulations are designed to further support couples on their fertility journey, as well as through their pregnancy.

Upon the company’s foundation nearly ten years ago, the founders were led by a simple statement when developing the pre-Conceive formulation. This statement is now the company motto; Research – Evidence – Result. These three simple words guide the company in its work and these four new additions to the Pillar Healthcare brand are formulated on the same principles.
The four new additions to the Pillar Healthcare range are:

  • Pillar Healthcare’s Methylfolate; an advanced form of folic acid, with superior absorption levels than the standard folic acid products, produced at the recommended dosage for pregnancy.
  • Pillar Healthcare’s Omega-3 for Pregnancy; a pure, contaminant and heavy-metal free Omega-3 fish oil, designed to support the health of both Mum and the developing Baby, including the development of the baby’s eyes, brain and their overall development.
  • Pillar Healthcare’s Ubiquinol Q10; designed in partnership with Kaneka, a global organisation who spent decades researching Coenzyme Q10. Pillar’s Ubiquinol is up to 18 times more absorbable than standard preparations, and it is clinically shown to improve fertility in men and women.
  • Pillar Healthcare’s Myo-Inositol; new research has shown that Myo-Inositol can improve the symptoms associated with PCOS in women and improve their hormonal profile and in men, Myo-Inositol has been studied to improve male fertility.

“It is a great day for the company. Pillar has been operating from our bases in Ireland and the Isle of Man, and our team has been fortunate to help thousands of couples to have healthy children,” said Mark Whitney, the company’s founder and developer of pre-Conceive.

Pillar Healthcare, which was founded in 2012, has been operating for nearly a decade. According to the World Health Organisation, “Government policies could mitigate the many inequities in access to safe and effective fertility care. To effectively address infertility, health policies need to recognise that infertility is a disease that can often be prevented, thereby mitigating the need for costly and poorly accessible treatments. Incorporating fertility awareness in national comprehensive sexuality education programmes, promoting healthy lifestyles to reduce behavioural risks, including prevention, diagnosis and early treatment of STIs, preventing complications of unsafe abortion, postpartum sepsis and abdominal/pelvic surgery, and addressing environmental toxins associated with infertility, are policy and programmatic interventions that all governments can implement.”

Mr. Whitney went on to say, “pre-Conceive provided an affordable and credible option when the product was launched in 2014, and the medical testimonials and patient endorsements tell you how successful it has been in changing people’s lives. These four new additions will support our work in helping people to conceive and support them during their pregnancy, for the best possible outcomes; happy mums, happy dads, and happy children.”

Key facts, according to the World Health Organisation.

  • Infertility is a disease of the male or female reproductive system defined by the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse.
  • Infertility affects millions of people of reproductive age worldwide – and has an impact on their families and communities. Estimates suggest that between 48 million couples and 186 million individuals live with infertility globally.
  • In the male reproductive system, infertility is most commonly caused by problems in the ejection of semen, absence or low levels of sperm, or abnormal shape (morphology) and movement (motility) of the sperm.
  • In the female reproductive system, infertility may be caused by a range of abnormalities of the ovaries, uterus, fallopian tubes, and the endocrine system, among others.
  • Infertility can be primary or secondary. Primary infertility is when a pregnancy has never been achieved by a person, and secondary infertility is when at least one prior pregnancy has been achieved.
  • Fertility care encompasses the prevention, diagnosis and treatment of infertility. Equal and equitable access to fertility care remains a challenge in most countries; particularly in low and middle-income countries. Fertility care is rarely prioritized in national universal health coverage benefit packages.

Please contact us at for additional information or if you have any questions for us.